Major Depressive Disorder (MDD) is a debilitating condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest in daily activities. Understanding its underlying causes and effective treatments is crucial for patient well-being. The Journal of Clinical Psychiatry provides a comprehensive look into MDD, offering evidence-based therapeutic approaches and the latest research findings. Our expert editors ensure content is relevant and actionable, aiding psychiatrists in offering holistic care to those grappling with depression.
Depression and Major Depressive Disorder
Page 2
Recently published articles about Depression (MDD)
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Original Research
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
Original Research
Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression
July 30, 2025
The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.
Original Research
Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial
July 30, 2025
Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.
